T. Nurminen

956 total citations
25 papers, 644 citations indexed

About

T. Nurminen is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, T. Nurminen has authored 25 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 13 papers in Immunology and 7 papers in Hematology. Recurrent topics in T. Nurminen's work include Spondyloarthritis Studies and Treatments (22 papers), Psoriasis: Treatment and Pathogenesis (11 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). T. Nurminen is often cited by papers focused on Spondyloarthritis Studies and Treatments (22 papers), Psoriasis: Treatment and Pathogenesis (11 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). T. Nurminen collaborates with scholars based in Germany, Netherlands and United States. T. Nurminen's co-authors include Antero Kallio, Eric Hollander, Gerard Smits, Jon E. Grant, Renee M. Cunningham‐Williams, Marc N. Potenza, Robert Landewé, Bengt Hoepken, O. Davies and Désirée van der Heijde and has published in prestigious journals such as American Journal of Psychiatry, Annals of the Rheumatic Diseases and Alcoholism Clinical and Experimental Research.

In The Last Decade

T. Nurminen

25 papers receiving 628 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Nurminen Germany	9	310	194	186	110	98	25	644
Joaquín A. Peña Venezuela	9	29 0.1×	34 0.2×	55 0.3×	19 0.2×	29 0.3×	28	370
Katy White United States	6	55 0.2×	192 1.0×	173 0.9×	31 0.3×	12 0.1×	14	430
J Kalina United States	6	51 0.2×	36 0.2×	22 0.1×	49 0.4×	25 0.3×	13	538
Chung‐Il Joung South Korea	10	39 0.1×	52 0.3×	26 0.1×	52 0.5×	21 0.2×	21	324
Hiromi Nabeta Japan	13	92 0.3×	102 0.5×	23 0.1×	10 0.1×	30 0.3×	27	373
B Weller Israel	8	58 0.2×	13 0.1×	38 0.2×	8 0.1×	59 0.6×	11	380
Salman Aljarallah Saudi Arabia	8	19 0.1×	46 0.2×	13 0.1×	21 0.2×	20 0.2×	31	321
Siobhán Kelly Ireland	14	51 0.2×	29 0.1×	57 0.3×	5 0.0×	23 0.2×	32	432
Leonie J. T. Balter Sweden	9	57 0.2×	48 0.2×	24 0.1×	39 0.4×	15 0.2×	26	383
Sidney Gomes Brazil	11	27 0.1×	17 0.1×	17 0.1×	24 0.2×	31 0.3×	22	311

Countries citing papers authored by T. Nurminen

Since Specialization

Citations

This map shows the geographic impact of T. Nurminen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Nurminen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Nurminen more than expected).

Fields of papers citing papers by T. Nurminen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Nurminen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Nurminen. The network helps show where T. Nurminen may publish in the future.

Co-authorship network of co-authors of T. Nurminen

This figure shows the co-authorship network connecting the top 25 collaborators of T. Nurminen. A scholar is included among the top collaborators of T. Nurminen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Nurminen. T. Nurminen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baraliakos, Xenofon, Natasha de Peyrecave, T. Nurminen, et al.. (2020). OP0104 THE IMPACT OF PERSISTENT INFLAMMATORY CHANGES ON PREVALENCE OF FATTY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: 4-YEAR MRI RESULTS FROM RAPID-AXSPA. Annals of the Rheumatic Diseases. 79. 67–68. 1 indexed citations

Coates, Laura C., Joseph F. Merola, Oliver FitzGerald, et al.. (2019). AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. Annals of the Rheumatic Diseases. 78. 1836–1837. 2 indexed citations

Baraliakos, Xenofon, Natasha de Peyrecave, T. Nurminen, et al.. (2019). FRI0385 LONG-TERM CERTOLIZUMAB PEGOL TREATMENT OF AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH RAPID AND SUSTAINED REDUCTION OF ACTIVE INFLAMMATION AND MINIMAL STRUCTURAL CHANGES IN THE SPINE: 4-YEAR MRI RESULTS FROM RAPID-AXSPA. Annals of the Rheumatic Diseases. 78. 876–877. 1 indexed citations

Heijde, Désirée van der, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2018). Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases. 77(5). 699–705. 90 indexed citations

Landewé, Robert, T. Nurminen, O. Davies, & Dominique Baeten. (2018). A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’. Arthritis Research & Therapy. 20(1). 209–209. 21 indexed citations

Gottlieb, Alice B., et al.. (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology. 37(12). 3285–3296. 12 indexed citations

Walsh, Jessica A., T. Arledge, T. Nurminen, Luke Peterson, & J. Stark. (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. The Journal of Rheumatology. 45(7). 922–928. 5 indexed citations

Heijde, D. van der, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2017). OP0023 Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Annals of the Rheumatic Diseases. 76. 60–61. 3 indexed citations

Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2017). Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 3(1). e000430–e000430. 29 indexed citations

10.

Rudwaleit, Martín, James T. Rosenbaum, Robert Landewé, et al.. (2016). Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care & Research. 68(6). 838–844. 65 indexed citations

11.

Heijde, Désirée van der, Atul Deodhar, Roy Fleischmann, et al.. (2016). Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis Care & Research. 69(7). 1030–1039. 17 indexed citations

12.

Heijde, Désirée van der, Walter P. Maksymowych, Robert Landewé, et al.. (2015). THU0201 Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks. Annals of the Rheumatic Diseases. 74. 268–268. 4 indexed citations

13.

Sieper, J., Martín Rudwaleit, Désirée van der Heijde, et al.. (2014). LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL. Clinical and Experimental Rheumatology. 32(5). 785–786. 1 indexed citations

14.

Rosenbaum, J. T., Martín Rudwaleit, Robert Landewé, et al.. (2014). Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.. Data Archiving and Networked Services (DANS). 66. 1 indexed citations

15.

Sieper, Joachim, A. Kivitz, Astrid van Tubergen, et al.. (2014). Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study. Value in Health. 17(7). A385–A386. 4 indexed citations

16.

Sieper, Joachim, Robert Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. Arthritis & Rheumatology. 67(3). 668–677. 50 indexed citations

17.

Helliwell, Philip, et al.. (2014). SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis. Annals of the Rheumatic Diseases. 73. 740–740. 3 indexed citations

18.

Mease, Philip J., Astrid van Tubergen, Atul Deodhar, et al.. (2013). Comparing Health-Related Quality of Life Across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data. Value in Health. 16(7). A570–A570. 4 indexed citations

19.

Karhuvaara, Sakari, Kaarlo Simojoki, Eliisa Löyttyniemi, et al.. (2007). Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double‐Blind Placebo‐Controlled Multicenter Study. Alcoholism Clinical and Experimental Research. 31(7). 1179–1187. 96 indexed citations

20.

Grant, Jon E., Marc N. Potenza, Eric Hollander, et al.. (2006). Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling. American Journal of Psychiatry. 163(2). 303–312. 219 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact